Imagine COPD as a fire in the lungs that current inhalers only blow air on to keep the smoke away. This project developed a pill that acts like a fire extinguisher, targeting the root cause of the inflammation. It blocks a specific receptor to stop the disease from getting worse, rather than just treating the symptoms.
COPD is the third leading cause of death worldwide, yet current treatments only relieve symptoms and do not stop the disease from progressing.
A first-in-class oral A1R antagonist (PBF-680) and the clinical evidence from a phase 2 trial showing reduced inflammation in COPD patients.
If you are a drug developer dealing with the lack of disease-modifying COPD therapies — this project developed PBF-680 that targets A1R signaling to reduce inflammation. It aims to move beyond symptom relief to actually slow disease progression.
If you are a clinic dealing with high hospitalization rates for 65 million COPD sufferers — this project developed an oral therapy that reduces circulating eosinophil levels. This could significantly lower healthcare costs and patient readmissions.
If you are an investor dealing with high-risk early-stage assets — this project developed a compound that has already passed phase 1 and phase 2 trials. It provides a clear path toward a phase 3 trial and market entry by 2032.
Based on available project data, specific pricing for the drug is not provided, though the project aims to lower overall healthcare costs related to hospitalizations.
The project has reached phase 2 clinical trial success; however, industrial scale manufacturing details are not specified in the provided data.
Based on available project data, PBF-680 is being developed by Palo Biofarma SL, but specific patent or licensing terms are not listed.
The company targets regulatory approval and market entry by 2032, following a planned phase 3 trial.
It is an oral medication designed to complement or replace current inhalers by modifying the disease course rather than just providing bronchodilation.
The project is led by a single partner, Palo Biofarma SL, a Spanish SME. This 100% industry-led structure indicates a highly focused commercial drive, with the company managing the entire clinical development pipeline from preclinical to phase 2 trials internally.
Contact Palo Biofarma SL in Spain regarding PBF-680 clinical partnerships.
Contact us to explore licensing opportunities for A1R antagonists.
